Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,523 across all filing types
Latest filing 2021-11-22 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT WITH KEYMED BIOSCIENCE (CHENGDU) CO., LTD. FOR CM326
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding an exclusive license agreement with Keymed Bioscience for a pharmaceutical product (CM326). It details the terms of the agreement, including payments and product information. There is no financial data, no regulatory filing references, no meeting or voting information, no audit or management report content, and no earnings or interim report data. The document is an announcement of a business transaction (licensing agreement) rather than a financial report or regulatory filing. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous filing that does not fit other categories, which is Regulatory Filings (RNS). The document length is about 4706 characters, which is not extremely short, but the content is clearly an announcement rather than a report or presentation.
2021-11-22 English
QUARTERLY RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2021
Interim / Quarterly Report Classification · 95% confidence The document is a detailed financial report presenting unaudited consolidated results for the nine months ended 30 September 2021. It includes comprehensive financial statements such as condensed consolidated statements of profit or loss, segment revenue and profit analysis, earnings per share calculations, and business review commentary. The presence of actual financial data, detailed segment information, and management discussion indicates this is a substantive interim financial report rather than a brief announcement or a certification. The period covered is less than a full fiscal year (nine months), which aligns with the definition of an Interim / Quarterly Report (IR). Therefore, the document is classified as an Interim / Quarterly Report (IR). 9M 2021
2021-11-18 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from CSPC Pharmaceutical Group Limited stating the date of a board meeting to approve the unaudited consolidated results for the nine months ended 30 September 2021. It does not contain any actual financial data or detailed results, only a notice of the upcoming board meeting and the intention to approve the results. The document length is only 1326 characters, which is quite short and fits the pattern of an announcement rather than a full interim or quarterly report. According to the MENU VS MEAL RULE, this is an announcement about a report, not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2021-11-08 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2021
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 October 2021. It details movements in issued shares, share options, and confirms compliance with listing rules. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital and share movements for a specific month. It does not contain financial statements, earnings data, or management discussion. It is a regulatory compliance filing related to share capital movements and confirmations, fitting the category of Regulatory Filings (RNS). The document length is about 6900 characters, which is substantive but not a full financial report. Therefore, the best classification is Regulatory Filings (RNS).
2021-11-01 English
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THIRD QUARTER OF 2021
Interim / Quarterly Report Classification · 95% confidence The document is an announcement by CSPC Pharmaceutical Group Limited regarding the principal financial information of its subsidiary CSPC Innovation Pharmaceutical Co., Ltd. for the third quarter of 2021. It references the subsidiary's 2021 Third Quarterly Report published on the Shenzhen Stock Exchange website. The document includes detailed financial data such as revenue, net profit, earnings per share, balance sheet items, income statement items, and cash flow statement items for the period ending September 30, 2021. The length of the document (11,511 characters) and the inclusion of substantive financial data and analysis indicate this is a comprehensive financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). It is not merely an announcement of a report or a certification, but contains actual financial statements and explanations. 9M 2021
2021-10-21 English
REVISION OF ANNUAL CAP FOR CONTINUING CONNECTED TRANSACTIONS
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the revision of an annual cap for continuing connected transactions under the Listing Rules of the Hong Kong Stock Exchange. It details the amendment of a steam supply agreement's annual cap, the parties involved, the reasons for the revision, and compliance with relevant listing rules. The document is structured as a formal announcement with no financial statements or detailed financial performance data. It is not a full annual report, interim report, earnings release, or management discussion and analysis. It is also not a proxy statement, voting results, or a regulatory filing of a different nature. The content fits the category of a Capital/Financing Update (CAP) because it relates to connected transactions and amendments to contractual financial limits, which are capital or financing related disclosures under Hong Kong Listing Rules. The document length (12,684 characters) and detailed content confirm it is a substantive announcement rather than a brief notice or report publication announcement.
2021-10-21 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.